SUMMARY A retrospective analysis of 350 treatment courses using high dose pulsed intravenous methylprednisolone for relapses of multiple sclerosis revealed a low number of adverse effects. This study confirms that high dose methylprednisolone is a safe therapeutic option in multiple sclerosis.
A small number of controlled clinical trials comparing short courses of prednisolone' or ACTH2 with a placebo have shown a limited beneficial effect in acute relapse of multiple sclerosis. Recently the effect of higher doses of steroid in shorter courses has been investigated and these studies have shown a favourable response when high dose pulsed intravenous methylprednisolone treatment is compared with ACTH3 or with placebo.4 Several uncontrolled studies using high dose methylprednisolone5 -7 have supported these findings, and all suggest that in addition to the beneficial aspects, such treatment is safe, well tolerated and with few adverse effects. The present study looks at a population of patients with multiple sclerosis treated with intravenous methylprednisolone with particular emphasis on the nature and frequency of unwanted effects.
Patients and methods
A retrospective review of case records gave a total of 240 patients having definite or probable multiple sclerosis treated between mid 1978 and 1987 with intravenous methylprednisolone pulse therapy. In nearly all cases there had been a worsening of symptoms in the weeks prior to the treatment, but in a few the intervention was an attempt to influence a chronic progressive course. One hundred and sixty four patients received a single course of treatment, 54 received two courses, 15 received three, five received four and there were two patients who received six and seven courses respectively, giving a total of 350 drug administrations. The average age at the time of treatment was 34 years with a range from 18 to 57 years. The standard treatment regime consisted of 1 g of intravenous methylprednisolone infused over 20 to 30 minutes, and administered daily for 5 days followed by oral prednisolone tailing from 60mg daily to zero over 10 days. The largest dose given to a single individual was a total of 30 g of methylprednisolone in six treatment episodes over 5 years. The patients were monitored before and during the treatment course and were usually reviewed at 1 to 3 months and then followed on a regular basis. progressed to a small bed sore following treatment, and in another patient a localised area of subcutaneous necrosis followed extravasation of part of the injection. Ten days following completion of treatment a deep vein thrombosis developed in one patient. A steroid "let down" was seen in a small group of patients but no Addison crises followed the abrupt withdrawal of the high dose steroid regime. During the period of follow up there have been no steroid induced cataracts and no avascular necrosis of bone.
Discussion and conclusions
Pulsed intravenous methylprednisolone is widely used in the treatment of immune mediated disorders and substantial experience has accrued in organ transplantation, rheumatoid arthritis and in other connective tissue diseases. In most cases it has been a safe treatment8-10 but cautionary reports of serious side effects have appeared; these include life threatening infections" and sudden death probably due to cardiac arrhythmia and circulatory collapse.'2 '3However, there has been a background of general debility in these patients who are therefore very different from the generally fit and comparatively young group of multiple sclerosis sufferers. The present study indicates the overall safety of pulsed methylprednisolone in the treatment of multiple sclerosis.
In non-neurological disease an association between high dose methylprednisolone and seizures has been observed in a number of instances12 1415 
